Correction to: The relationship between imaging features, therapeutic response, and overall survival in pediatric diffuse intrinsic pontine glioma
Xiaojun Yu, Mingyao Lai, Juan Li, Lichao Wang, Kunlin Ye, Dong Zhang, Qingjun Hu, Shaoqun Li, Xinpeng Hu, Qiong Wang, Mengjie Ma, Zeyu Xiao, Jiangfen Zhou, Changzheng Shi, Liangping Luo, Linbo Cai
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGlioma Diagnosis and Treatment
Correction to: Neurosurgical Review
10.1007/s10143-024-02435-8
The authors regret that the version of Table 3 that appears in the original published article contains some errors.
The incorrect Table 3 appears below.
Table 3. Univariate and multivariate analyses of the correlations of clinical and imaging features and therapeutic responses with overall survival VariableHRP valueUnivariateAge (continuous)0.064Age (Categorical)0.106 ≤ 3 > 3Karnofsky score0.97 (0.96–0.98)< 0.001^^Tumor CP Size0.296Tumor volume0.256Craniocaudal dimension0.366Necrosis (55/116)1.72 (1.20–2.46)0.003^^Ring enhancement (52/116)1.69 (1.18–2.43)0.004^^Extrapontine lesion extension ratio (× 100%)1.04 (1.02–1.06)< 0.001^^Therapeutic response (CP reduction of 25%)< 0.001^^ PR (n = 63)1.00 Non-PR (SD (n = 64)/PD (n = 7))2.27 (1.57–3.27)Therapeutic response (volume reduction of 32%)< 0.001^^ PR (n = 71)1.00 Non-PR (SD (n = 56)/PD (n = 7))2.50 (1.74–3.61)Post-radiotherapy increased ring enhancement (54/134) (42/108+)2.16 (1.50–3.10)< 0.001^^MultivariateKarnofsky score0.97 (0. 96–0.99)< 0.001^^Necrosis1.55 (1.08–2.23)0.017^*^Extrapontine lesion extension ratio (× 100%)1.03 (1.01–1.05)0.006^^Therapeutic response (volume reduction of 32%)0.008^^ PR1.00 Non-PR (SD/PD)1.73 (1.15–2.61)
^^ P < 0.05, ^^ P < 0.01, ^^ P < 0.001.
Jiangfen ZhouAbbreviations: PR, partial response; SD, stable disease; PD, progressive disease; CP, cross-product; HR, hazards ratio
The correct Table 3 is shown below.
Table 3. Univariate and multivariate analyses of the correlations of clinical and imaging features and therapeutic responses with overall survival VariableHRP** valueUnivariateAge (continuous)0.064Age (Categorical)0.106 ≤ 3 > 3Karnofsky score0.97 (0.96–0.98)< 0.001^^Tumor CP Size0.296Tumor volume0.256Craniocaudal dimension0.366Necrosis (55/134)1.72 (1.20–2.46)0.003^^Ring enhancement (52/134)1.69 (1.18–2.43)0.004^^Extrapontine lesion extension ratio (× 100%)1.04 (1.02–1.06)< 0.001^^Therapeutic response (CP reduction of 25%)< 0.001^^ PR (n = 63)1.00 Non-PR (SD (n = 64)/PD (n = 7))2.27 (1.57–3.27)Therapeutic response (volume reduction of 32%)< 0.001^^ PR (n = 71)1.00 Non-PR (SD (n = 56)/PD (n = 7))2.50 (1.74–3.61)Post-radiotherapy increased ring enhancement (54/134)2.16 (1.50–3.10)< 0.001^^MultivariateKarnofsky score0.97 (0. 96–0.99)< 0.001^^Necrosis1.55 (1.08–2.23)0.017^*^Extrapontine lesion extension ratio (× 100%)1.03 (1.01–1.05)0.006^^Therapeutic response (volume reduction of 32%)0.008^**^ PR1.00 Non-PR (SD/PD)1.73 (1.15–2.61) * P < 0.05, ** P < 0.01, *** P < 0.001. PR, partial response; SD, stable disease; PD, progressive disease; CP, cross-product; HR, hazards ratioThe original article has been corrected.